The COVID-19 pandemic has had tremendous impact worldwide but possibly no other patient subset has been impacted as much as patients with a cancer diagnosis. Significantly increased morbidity and mortality was defined amongst identifiable subsets of cancer patients, such as the elderly, patients with co-morbid illnesses and certain malignancy types and therapies. In addition, major compromises in cancer care and drastic drop-offs in cancer screening rates have led to significant further setbacks in recent advances in cancer care. Emerging information as to the benefit of COVID-19 vaccinations, including booster vaccines that can benefit even the most immune suppressed along with novel anti-COVID antibodies preemptively reduce the risk of infection. Antiviral and other therapeutics mitigating the severity of COVID-19 infections now offer major insights, new and effective options and hope for being able to optimize cancer care even in the face of the ongoing pandemic.
|Number of pages||7|
|State||Published - Mar 28 2022|
ASJC Scopus subject areas